ZYME - Zymeworks Stock Price, News & Analysis

$8.27 0.11 (1.35 %)
(As of 11/23/2017 01:22 PM ET)
Previous Close$8.16
Today's Range$8.21 - $8.30
52-Week Range$6.25 - $14.25
Volume11,200 shs
Average Volume23,387 shs
Market Capitalization$207.08 million
P/E RatioN/A
Dividend YieldN/A

About Zymeworks (NYSE:ZYME)

Zymeworks logoZymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
  • Previous Symbol: NASDAQ:ZYME


    Debt-to-Equity RatioN/A
    Current Ratio4.57%
    Quick Ratio4.57%


    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual Sales$11 million
    Price / Sales19.08
    Cash FlowN/A
    Price / CashN/A
    Book Value$3.25 per share
    Price / Book2.54


    Annual DividendN/A
    Dividend YieldN/A


    Trailing EPSN/A
    Net Income$-33,800,000.00
    Net Margins-1,387.89%
    Return on Equity-117.85%
    Return on Assets-54.48%


    Outstanding Shares25,380,000

    Frequently Asked Questions for Zymeworks (NYSE:ZYME)

    What is Zymeworks' stock symbol?

    Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

    How were Zymeworks' earnings last quarter?

    Zymeworks Inc. (NYSE:ZYME) released its quarterly earnings results on Monday, May, 15th. The company reported ($1.13) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter. Zymeworks had a negative net margin of 1,387.89% and a negative return on equity of 117.85%. View Zymeworks' Earnings History.

    When will Zymeworks make its next earnings announcement?

    Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Zymeworks.

    Where is Zymeworks' stock going? Where will Zymeworks' stock price be in 2017?

    6 brokerages have issued 12-month price targets for Zymeworks' shares. Their predictions range from $8.00 to $20.00. On average, they anticipate Zymeworks' stock price to reach $16.00 in the next year. View Analyst Ratings for Zymeworks.

    Who are some of Zymeworks' key competitors?

    Who are Zymeworks' key executives?

    Zymeworks' management team includes the folowing people:

    • Nick Bedford, Chairman of the Board
    • Ali Tehrani Ph.D., President, Chief Executive Officer, Director
    • Neil Klompas, Chief Financial Officer
    • Surjit Dixit Ph.D., Chief Technology Officer
    • Diana Hausman M.D., Chief Medical Officer (Age 52)

    When did Zymeworks IPO?

    (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

    When did Zymeworks' lock-up period expire?

    Zymeworks' lock-up period expired on Wednesday, October 25th. Zymeworks had issued 4,500,000 shares in its public offering on April 28th. The total size of the offering was $58,500,000 based on an initial share price of $13.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

    How do I buy Zymeworks stock?

    Shares of Zymeworks can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Zymeworks' stock price today?

    One share of Zymeworks stock can currently be purchased for approximately $8.27.

    How big of a company is Zymeworks?

    Zymeworks has a market capitalization of $207.08 million and generates $11 million in revenue each year. Zymeworks employs 136 workers across the globe.

    How can I contact Zymeworks?

    Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

    MarketBeat Community Rating for Zymeworks (ZYME)

    Community Ranking:  2.7 out of 5 (star star)
    Outperform Votes:  52 (Vote Outperform)
    Underperform Votes:  45 (Vote Underperform)
    Total Votes:  97
    MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Zymeworks (NYSE:ZYME)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 2 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
    Consensus Rating:Hold (Score: 2.33)
    Consensus Price Target: $16.00 (93.47% upside)

    Consensus Price Target History for Zymeworks (NYSE:ZYME)

    Price Target History for Zymeworks (NYSE:ZYME)

    Analysts' Ratings History for Zymeworks (NYSE:ZYME)

    DateFirmActionRatingPrice TargetImpact on Share PriceDetails
    9/30/2017CormarkReiterated RatingBuyMediumView Rating Details
    9/7/2017ScotiabankDowngradeOverweight -> UnderweightHighView Rating Details
    9/7/2017Barclays PLCReiterated RatingOverweight -> Underweight$8.00HighView Rating Details
    5/23/2017Citigroup Inc.Initiated CoverageBuy -> Buy$18.00LowView Rating Details
    5/23/2017Wells Fargo & CompanyInitiated CoverageOutperform -> Outperform$20.00LowView Rating Details
    5/23/2017Canaccord GenuityInitiated CoverageBuy -> Buy$18.00LowView Rating Details
    (Data available from 11/23/2015 forward)


    Earnings History and Estimates Chart for Zymeworks (NYSE:ZYME)

    Earnings by Quarter for Zymeworks (NYSE:ZYME)

    Earnings History by Quarter for Zymeworks (NYSE ZYME)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    5/15/2017Q1($1.13)$0.23 millionViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)


    Earnings Estimates for Zymeworks (NYSE:ZYME)
    Current Year EPS Consensus Estimate: $-3.09 EPS
    Next Year EPS Consensus Estimate: $-2.6 EPS


    Dividend History for Zymeworks (NYSE:ZYME)
    No dividend announcements for this company have been tracked by MarketBeat.com

    Insider Trades

    Insider Trading History for Zymeworks (NYSE ZYME)
    No insider trades for this company have been tracked by MarketBeat.com


    Latest Headlines for Zymeworks (NYSE ZYME)

    Zymeworks Inc. (ZYME) Receives Average Recommendation of "Hold" from BrokeragesZymeworks Inc. (ZYME) Receives Average Recommendation of "Hold" from Brokerages
    www.americanbankingnews.com - November 21 at 8:24 AM

    Social Media


    Financials are not available for this stock.


    Zymeworks (NYSE ZYME) Chart for Thursday, November, 23, 2017
    Loading chart…

    This page was last updated on 11/23/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.